|
Current & future perspectives in psychiatric drug discovery
12th March 2009 |
|
| Programme: | |
| 09.30 | Registration and coffee |
| Session 1 - Chair: Eric Karran, Johnson & Johnson | |
| 10.00 |
Trevor Robbins, Cambridge University,
UK 'Cognitive enhancement in schizophrenia, depression and addiction: Prospects and pitfalls' |
| 11.00 |
Mark Tricklebank, Lilly, UK Cognition in animals: measurement and application to neuroscience drug discovery for schizophrenia |
| 11.40 |
Ian Wilson, GE Healthcare Medical
Diagnostics, UK Development of a Neurology & Psychiatry Imaging Toolbox |
| 12.20 | Lunch |
| Session 2 - Chair: Wendy Alderton, Summit plc | |
| 13.20 |
Bob Alexander, GlaxoSmithKline Clinical perspective: new therapeutic approaches for treating Depression |
| 14.00 |
Brian O’Neill, Pfizer, USA Smoking cessation: varenicline, an a4β2 partial agonist |
| 14.50 | Tea |
| Session 3 - Chair: Simon Ward, GlaxoSmithKline | |
| 15.20 |
Gregor Macdonald, Johnson & Johnson Research and Early Development
(RED) Europe, Belgium A 'Fast' Track to Atypicality - The Discovery of JNJ37822681 for the Treatment of Schizophrenia |
| 16.00 |
Frank Menniti, Pfizer, USA PDE10 inhibitors for psychiatric disorders |
| 16.40 | Close |
| Home / Meetings / Membership / Student Bursaries / Administration / History of the SMR / SMR Award / Archive Material / Links / Contact Us |